GPER was first demonstrated to be responsible for estrogen’s activation of the MAP kinases ERK1/2 in ERα-and ERβ-negative breast cancer cells, through a mechanism involving the transactivation of epidermal growth factor receptor (EGFR) by metalloproteinase-released HB-EGF [27]. This evidence concerns the gene GPER1 and breast carcinoma.